Back

FINARM study versus FINE-HEART pooled analysis: comparative analysis of patients with heart failure and diabetic kidney disease

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: From genetics to AI: advancing risk prediction and diagnosis in heart failure Epidemiology, Prognosis, Outcome HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Mr Edison Omar Boada Lincango

A Coruna University Hospital, A Coruna (Spain)

5 More presentations in this session

Presentation thumbnail
Valvular heart disease and its association with mortality in advanced heart failure
Doctor K. Steiger (Rochester, US)
Abstract Slides Video
Presentation thumbnail
Early clinical manifestations and time-to-diagnosis in patients with ATTR amyloidosis with mixed phenotype - results from the OverTTuRe study
Doctor L. Anderson (London, GB)
Abstract Slides Video
Presentation thumbnail
Time from first recorded clinical manifestation to diagnosis of transthyretin amyloid cardiomyopathy: a retrospective cohort study using US claims data
Associate Professor J. Mitchell (St Louis, US)
Abstract Slides Video
Presentation thumbnail
Evaluating machine learning-based data extraction for heart failure management: a step toward optimized therapy
Doctor J. Zmazek (Maribor, SI)
Abstract Slides Video
Presentation thumbnail
Genome-wide association study of clinical outcomes in heart failure and Mendelian randomisation analysis of the impact of elevated body mass index on disease progression
Doctor N. Sunderland (Bristol, GB)
Abstract Slides Video

Access the full session

Session thumbnail
From genetics to AI: advancing risk prediction and diagnosis in heart failure

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Epidemiological profile of heart failure patients with diabetic kidney disease initiating finerenone: insights from real-world data (FINARM STUDY)
thumbnail
Congress Presentation
The applicability of finerenone therapy across the broad spectrum of cardiovascular-kidney-metabolic syndrome: shaken not stirred
thumbnail
Congress Presentation
Real-world eligibility for finerenone in diabetic patients with chronic kidney disease: insights from the FIDELITY pooled analysis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources